Fennec licenses PEDMARQSI to Norgine for EU/AU/NZ; €40M upfront, up to €210M milestones

FENNEC PHARMACEUTICALS INC.

Exclusive license covers Europe (incl. UK), Australia, New Zealand; Norgine to commercialize.
Fennec receives €40M upfront paid March 15, 2024, plus up to €210M in regulatory/commercial milestones.
Tiered royalties on net sales range from mid-teens to mid-twenties percent.
PEDMARQSI is first EU/U.K.-approved therapy to reduce cisplatin-induced hearing loss in pediatric patients.
Estimated >5,000 pediatric patients/year eligible in Europe; approvals based on Phase 3 trials showing ~50% hearing loss reduction.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

FENNEC PHARMACEUTICALS INC. entered into License and Supply Agreement with Norgine Pharma UK Limited valued at €40 million (effective 2024-03-15).

Action: entry
Agreement: license
Counterparty: Norgine Pharma UK Limited
Value: €40 million
Effective: 2024-03-15

Exact text from the filing

On March 15, 2024, Fennec Pharmaceuticals, Inc., a Delaware corporation (“Fennec”) and wholly owned subsidiary of Fennec Pharmaceuticals Inc. (the “Company”), entered into a License and Supply Agreement (the “Agreement”) with Norgine Pharma UK Limited (“Norgine”)

View on SEC.gov

547 material agreements filed in the last 30 days. Browse all material agreements →

FENNEC PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-037255

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.